Business context and reporting period
Entity and period: The supplied filing is TapImmune Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed April 15, 2015. This does not match the request metadata identifying Marker Therapeutics, Inc. or “2014 Q4.” The filing describes TapImmune as a clinical-stage biotechnology company developing cancer immunotherapies and vaccine technologies.
The company’s lead programs were Phase I HER2/neu breast cancer and Folate Receptor Alpha breast and ovarian cancer vaccine studies, conducted with Mayo Clinic. Management planned to evaluate both for Phase II advancement in 2015. The company had no product revenue and reported one full-time employee, supplemented by consultants and collaborators.
Financial results and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | None reported | None reported |
| Operating expenses | $3.371 million | $2.664 million |
| Net loss | $30.883 million | $5.533 million |
| Basic and diluted loss per share | $2.00 | $4.87 |
| Cash used in operations | $2.187 million | $0.695 million |
| Cash provided by financing | $2.281 million | $0.709 million |
| Cash at year-end | $142,000 | $49,000 |
| Working capital | $(1.024) million | $(8.768) million |
The 2014 net loss included a $26.884 million loss on extinguishment of debt, primarily associated with debt and payable conversions into equity. General and administrative expense rose to $3.182 million from $1.967 million, including $1.391 million of stock-based compensation versus $85,000 reported in management’s discussion. Research and development expense declined to $189,000 from $698,000.
At December 31, 2014, total assets were $224,000 and current liabilities were $1.248 million. Convertible notes payable fell from $3.162 million to zero; related-party promissory notes remained at $53,000, research agreement obligations were $492,000, accounts payable and accrued liabilities were $693,000, and warrant derivative liability was $9,000. Stockholders’ deficit was $1.024 million, compared with $8.768 million a year earlier.
Material changes versus the prior comparable period
- Net loss increased substantially, driven mainly by the non-cash debt-extinguishment loss; operating expenses increased by about $707,000.
- Debt restructuring converted approximately $4.7 million of debt and $0.5 million of accrued interest into preferred stock that immediately converted into about 14.0 million common shares. The filing reports a fair value of approximately $31 million for the shares issued in these conversions.
- The February 2014 1-for-100 reverse stock split and increase in authorized common shares from 150 million to 500 million materially changed the share count and capital structure. Weighted-average shares rose to 15.465 million from 1.136 million; per-share comparisons are affected by the reverse split and issuance of shares.
- Cash remained limited despite improved working capital and reduced recorded debt. Operating cash use exceeded cash on hand at year-end.
Outlook, commentary, risks and unusual items
- Funding and going concern: The auditor and management disclosed substantial doubt about the company’s ability to continue as a going concern. The company had accumulated losses of $86.310 million, no revenue, negative working capital, and depended on additional financing, debt accommodations and partnerships. Management estimated spending of approximately $7.5 million over the following 12 months, subject to financing, and warned that insufficient funding could force it to scale back or abandon plans.
- Subsequent financings: The filing reports January and March 2015 unit offerings, each including common shares and multiple warrant series, with net proceeds stated as approximately $1.25 million and $950,000, respectively. These transactions increased potential dilution; the filing reports 65.25 million common-stock purchase warrants outstanding as of April 10, 2015.
- Clinical outlook: Management expected to assess Phase II advancement of both lead programs in 2015. Interim data cited in the filing reported no serious adverse events to date in the Folate Receptor Alpha trial and immune responses in 20 of 21 evaluable patients. In the HER2/neu study, the first six patients reportedly showed safety and antigen-specific immune responses. These are interim findings, not evidence of clinical efficacy or regulatory approval.
- Development priorities: Management intended to advance the HER2/neu and Folate Receptor Alpha programs, develop its Polystart technology, and seek non-dilutive grants or partners for infectious-disease work. The company discontinued plans to fund primate studies for its smallpox program with internal resources.
- Contingencies: The company was attempting to collect a $196,204 arbitration award plus 9% annual interest from a former consultant. It also disclosed a $51,000 supplier judgment it intended to settle in 2015, and a $492,365 accrued obligation under a research license agreement.
- Reporting and operational risks: Management concluded disclosure controls and internal control over financial reporting were ineffective and identified material weaknesses involving board and audit-committee oversight, segregation of duties, written accounting procedures, and period-end reporting. The company also disclosed that it had not filed U.S. tax returns since inception and was preparing past returns; possible Canadian filing penalties were unquantified.
- The filing identifies clinical, regulatory, intellectual-property, competition, key-personnel and financing risks. The company did not maintain product-liability insurance because it was not yet selling products.
Important facts for investors to verify
- Confirm the issuer and period: this is TapImmune Inc.’s FY 2014 Form 10-K, not a filing identified in the request metadata as Marker Therapeutics, Inc. or 2014 Q4.
- Review audited statements and debt-conversion accounting underlying the $26.884 million extinguishment loss, including the valuation of shares issued to settle obligations.
- Check cash runway, subsequent financing proceeds, offering costs, warrant terms and fully diluted share count; the filing gives differing share-count snapshots at year-end and after subsequent transactions.
- Seek updated, complete clinical-trial results and distinguish immune-response and safety observations from demonstrated clinical benefit.
- Track resolution of the going-concern uncertainty, supplier and research-license obligations, arbitration-award collection, tax filings, and remediation of the disclosed control weaknesses.